Probity Advisors Inc. Purchases 671 Shares of Sanofi (NASDAQ:SNY)

Probity Advisors Inc. increased its position in Sanofi (NASDAQ:SNY) by 4.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 14,413 shares of the company’s stock after buying an additional 671 shares during the quarter. Probity Advisors Inc.’s holdings in Sanofi were worth $831,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of SNY. POM Investment Strategies LLC bought a new stake in shares of Sanofi in the 2nd quarter worth approximately $25,000. Register Financial Advisors LLC bought a new position in shares of Sanofi during the 1st quarter valued at $29,000. Larson Financial Group LLC raised its position in Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares during the period. Palisade Asset Management LLC bought a new stake in Sanofi in the first quarter worth $31,000. Finally, Arrow Financial Corp bought a new stake in Sanofi in the second quarter worth $35,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

SNY has been the subject of a number of recent research reports. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus lifted their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Monday. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Trading Up 0.4 %

NASDAQ SNY opened at $54.66 on Thursday. Sanofi has a 12 month low of $42.63 and a 12 month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock’s fifty day moving average price is $56.00 and its 200-day moving average price is $51.46. The stock has a market cap of $138.44 billion, a P/E ratio of 27.36, a P/E/G ratio of 1.56 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.95 EPS. As a group, equities analysts forecast that Sanofi will post 4.25 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.